• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (NQ:KNSA)

    38.64 -0.28 (-0.72%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 361,365
    Open 38.90
    Bid (Size) 38.62 (7)
    Ask (Size) 38.65 (1)
    Prev. Close 38.92
    Today's Range 37.85 - 39.14
    52wk Range 17.82 - 39.43
    Shares Outstanding 71,726,685
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    5 Analysts Have This To Say About Kiniksa Pharmaceuticals
     
    Via Benzinga
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Identified by High Growth Momentum and Minervini Trend Screen
    Kiniksa Pharma (KNSA) is a high-growth momentum stock in a strong technical uptrend, with surging earnings and sales supporting its price advance. 
    Via Chartmill

    Performance

    YTD
    +93.8%
    +93.8%
    1 Month
    +8.0%
    +8.0%
    3 Month
    +34.0%
    +34.0%
    6 Month
    +91.2%
    +91.2%
    1 Year
    +46.8%
    +46.8%

    More News

    Read More
    What Analysts Are Saying About Kiniksa Pharmaceuticals Stock
    Via Benzinga
    Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup
    Via Chartmill
    Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Emerges as an Affordable Growth Opportunity
    Via Chartmill
    Earnings Scheduled For July 29, 2025
    Via Benzinga
    Earnings Preview: Kiniksa Pharmaceuticals
    Via Benzinga
    Earnings Scheduled For April 29, 2025
    Via Benzinga
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top Affordable Growth Candidate
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Exhibits High Growth Momentum and Technical Breakout Potential
    Via Chartmill
    KINIKSA PHARMACEUTICALS INTE (NASDAQ:KNSA): A Strong Growth Stock with a Positive Technical Breakout
    Via Chartmill
    Kiniksa Pharmaceuticals International (NASDAQ:KNSA) – An Affordable Growth Stock with Strong Fundamentals and Fair Valuation
    Via Chartmill
    Kiniksa Pharmaceuticals (NASDAQ:KNSA) Aligns with Minervini’s Trend Model as a Strong Momentum Pick
    Via Chartmill
    Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
    Via The Motley Fool
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
    Via Benzinga
    Topics Artificial Intelligence
    Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
    From Kiniksa Pharmaceuticals, Ltd.
    Via GlobeNewswire
    These stocks are gapping in today's session
    Via Chartmill
    Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook
    Via Benzinga
    3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
    Via The Motley Fool
    Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
    Via Benzinga

    Frequently Asked Questions

    Is Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares publicly traded?
    Yes, Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares is publicly traded.
    What exchange does Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares trade on?
    Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares?
    The ticker symbol for Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares is KNSA on the Nasdaq Stock Market
    What is the current price of Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares?
    The current price of Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares is 38.64
    When was Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares last traded?
    The last trade of Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares was at 10/17/25 04:00 PM ET
    What is the market capitalization of Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares?
    The market capitalization of Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares is 2.77B
    How many shares of Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares are outstanding?
    Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.